Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cinemark Holdings Inc CNK

Cinemark Holdings, Inc. is a movie theatre company. The Company is engaged in the motion picture exhibition industry, with theaters in the United States, Brazil, Argentina, Chile, Colombia, Peru, Honduras, El Salvador, Nicaragua, Costa Rica, Panama, Guatemala, Bolivia, and Paraguay. Its segments include U.S. markets and international markets. Its circuit, comprised of various brands that also include Century, Tinseltown and Rave, operates approximately 497 theaters with 5,653 screens in 42 states domestically and 13 countries throughout South and Central America. It plays mainstream films from many different genres, such as animated films, family films, dramas, comedies, horror and action films. It offers content in both 2-D and 3-D formats in all of its theaters, and in many locations, it offers either its own premium large format, XD, IMAX or ScreenX. It offers a variety of alternative entertainment content for its guests, such as concert, sporting and gaming events, and others.


NYSE:CNK - Post by User

User Avatar Image
(0)
•••
  • Denver67X
Post by Denver67on Jun 03, 2022 5:06am
156 Views
Post# 34728740

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance




FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


<< Previous
Bullboard Posts
Next >>